Sientra Wins Premier’s Horizon Award for 2022 for Exceptional Customer Service, Engagement, and Value Creation


Sientra Wins Premier’s Horizon Award for 2022 for Exceptional Customer Service, Engagement, and Value Creation

SANTA BARBARA, Calif., July 11, 2022 -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a leading medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, was recently honored with the 2022 Supplier Horizon Award. Sientra was honored at the Annual Premier Breakthroughs Conference that took place from June 21-23, 2022, in National Harbor, Maryland. 

The award recognizes suppliers that demonstrate unwavering commitment to delivering top value products and services designed to continually improve patient care. The Horizon Award specifically recognizes suppliers -- with less than three years of Premier tenure in a specific service line -- that consistently support Premier members at the highest levels of partnership, customer service, value creation, clinical excellence, and commitment to lower costs.

“We are pleased to be recognized for our commitment to our customers and patients,” commented Ron Menezes, CEO of Sientra. “As we position Sientra for continuing our accelerated growth in the next couple of years and work to become the market leader in reconstruction, we remain committed to safety and to providing an exceptional experience for our customers and patients. This award underscores our values as a company and demonstrates the partnership benefits we provide our customers by doing things differently, and keeping our standards high.”

With hospitals returning to pre-pandemic reconstruction volumes, Sientra is in a strong position to continue to gain market share and recently announced its seventh consecutive quarter of growth, year-over-year. Sientra has a strong portfolio of products that support the reconstruction market with their state-of-the-art Sientra breast implants and ground-breaking dual-port breast tissue expander, AlloX2® and recently launched their Dermaspan® breast tissue expander featuring 6 tabs. These products offer leading transformative treatments and technologies focused on progressing the art of plastic surgery and making a difference in patients’ lives. 


About Sientra

Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons (*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at
(*) Data on file


Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are made only as of the date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Forward-looking statements may include information concerning the the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, profitability, outlook and overall business strategy, the Company’s assumptions about the market and market growth, the reception of plastic surgeons to the Company’s products, and the Company’s ability to capture additional market share and customer accounts in the plastic surgery market. Such statements are subject to risks and uncertainties, including the Company’s ability to recapture delayed procedures resulting from the COVID-19 pandemic, the positive reaction from plastic surgeons and their patients to the Company’s products, the growth of the plastic surgery market and breast procedures, and the ability of the Company to execute on its commercial, marketing, research and development and regulatory plans. Additional factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Sientra’s public filings with the Securities and Exchange Commission. All statements other than statements of historical fact are forward-looking statements. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, and such estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.


Investor Relations Contact
Aman R. Patel, CFA

Nasdaq: SIEN

Stock Quote: NASD

$0.26 +0.01
Volume 173,411
Previous Close 0.25
Intraday High 0.27
Intraday Low 0.24
Pricing delayed 20 minutes
Price Change % Change +4.21% 52 Week High 4.43 52 Week Low 0.16 Today's Open 0.27 Dec 07, 2022 11:05 AM

Investor Contact

Sientra Investor Relations